Loading...
XSHE300016
Market cap406mUSD
Jan 09, Last price  
6.06CNY
1D
0.00%
1Q
5.03%
Jan 2017
-50.79%
IPO
26.64%
Name

Beijing Beilu Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:300016 chart
P/E
—
P/S
3.35
EPS
—
Div Yield, %
1.70%
Shrs. gr., 5y
-0.58%
Rev. gr., 5y
7.93%
Revenues
891m
+16.30%
83,940,018125,728,776232,090,873177,222,067216,810,922182,051,933196,701,996273,979,343331,615,821439,980,365491,430,959498,860,618522,538,130608,053,473819,119,389827,337,626843,901,446765,881,882890,718,122
Net income
-72m
L
9,140,06512,291,56227,668,38626,053,62434,863,24442,772,51544,211,75163,038,70565,971,72086,768,93832,579,24416,379,483118,816,656147,761,859342,438,319174,701,969125,514,72011,283,927-71,757,140
CFO
62m
-51.10%
19,647,35012,275,853057,911,73237,514,83945,726,98922,856,05841,369,95142,107,53680,853,23476,167,184144,924,876175,754,189156,808,658176,002,788108,726,227127,812,75762,497,843
Dividend
May 25, 20230.07 CNY/sh
Earnings
May 13, 2025

Profile

Beijing Beilu Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd. also produces precision medicine. The company was founded in 1992 and is based in Beijing, China.
URL
http://www.beilu.com.cn
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
890,718
16.30%
765,882
-9.25%
Cost of revenue
938,302
670,181
Unusual Expense (Income)
NOPBT
(47,584)
95,700
NOPBT Margin
12.50%
Operating Taxes
Tax Rate
NOPAT
(47,584)
95,700
Net income
(71,757)
-735.92%
11,284
-91.01%
Dividends
(50,718)
(34,338)
Dividend yield
1.49%
1.07%
Proceeds from repurchase of equity
(100)
BB yield
0.00%
Debt
Debt current
187,961
120,852
Long-term debt
606,887
536,248
Deferred revenue
11,741
7,889
Other long-term liabilities
1
Net debt
(509,660)
(685,611)
Cash flow
Cash from operating activities
62,498
127,813
CAPEX
(144,609)
Cash from investing activities
(114,319)
Cash from financing activities
53,172
FCF
(134,024)
44,918
Balance
Cash
748,446
766,735
Long term investments
556,062
575,977
Excess cash
1,259,972
1,304,417
Stockholders' equity
1,503,328
1,794,694
Invested Capital
1,325,760
1,268,053
ROIC
7.62%
ROCE
3.64%
EV
Common stock shares outstanding
478,381
491,957
Price
7.12
9.20%
6.52
-28.98%
Market cap
3,406,072
6.19%
3,207,557
-27.62%
EV
3,032,108
2,668,846
EBITDA
36,878
173,350
EV/EBITDA
82.22
15.40
Interest
53,138
47,644
Interest/NOPBT
49.78%